Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation.

Keating SM, Taylor DL, Plant AL, Litwack ED, Kuhn P, Greenspan EJ, Hartshorn CM, Sigman CC, Kelloff GJ, Chang DD, Friberg G, Lee JSH, Kuida K.

Clin Transl Sci. 2018 May;11(3):267-276. doi: 10.1111/cts.12536. Epub 2018 Mar 2. Review.

2.

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Keeney M, Wood BL, Hedley BD, DiGiuseppe JA, Stetler-Stevenson M, Paietta E, Lozanski G, Seegmiller AC, Greig BW, Shaver AC, Mukundan L, Higley HR, Sigman CC, Kelloff G, Jessup JM, Borowitz MJ.

Cytometry B Clin Cytom. 2018 Mar;94(2):239-249. doi: 10.1002/cyto.b.21528. Epub 2017 May 5.

3.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

4.

Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform.

Kuhn P, Keating SM, Baxter GT, Thomas K, Kolatkar A, Sigman CC.

Clin Pharmacol Ther. 2017 Nov;102(5):777-785. doi: 10.1002/cpt.645. Epub 2017 Mar 22. Review.

5.

Biomarker development in the context of urologic cancers.

Kelloff GJ, Sigman CC, Scher HI.

Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Review.

6.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

7.

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.

Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.

8.

Considerations in the development of circulating tumor cell technology for clinical use.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ.

J Transl Med. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138. Review.

9.

Cancer biomarkers: selecting the right drug for the right patient.

Kelloff GJ, Sigman CC.

Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14. doi: 10.1038/nrd3651. Review.

PMID:
22322254
10.

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee.

Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.

11.

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI.

J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.

12.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.

PMID:
19440188
13.

Early detection of oral neoplasia: watching with new eyes.

Kelloff GJ, Sigman CC, Contag CH.

Cancer Prev Res (Phila). 2009 May;2(5):405-8. doi: 10.1158/1940-6207.CAPR-09-0064. Epub 2009 Apr 28. Review. No abstract available.

14.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
15.

The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention.

Kopelovich L, Fay JR, Sigman CC, Crowell JA.

Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1330-40. Review.

16.

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.

Kelloff GJ, Sigman CC.

Nat Rev Cancer. 2007 Jul;7(7):508-18. Review.

PMID:
17568791
17.

FDG-PET lymphoma demonstration project invitational workshop.

Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J.

Acad Radiol. 2007 Mar;14(3):330-9.

PMID:
17307666
18.

Chemoprevention strategies in the prostate: an overview.

Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED.

Rev Urol. 2002 Spring;4(2):69-77.

19.

Imaging and oncologic drug development.

El-Deiry WS, Sigman CC, Kelloff GJ.

J Clin Oncol. 2006 Jul 10;24(20):3261-73. Review.

PMID:
16829650
20.

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention.

Clin Cancer Res. 2006 Jun 15;12(12):3661-97. Review.

21.

The progress and promise of molecular imaging probes in oncologic drug development.

Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J.

Clin Cancer Res. 2005 Nov 15;11(22):7967-85. Review.

22.

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC.

Clin Cancer Res. 2005 Apr 15;11(8):2785-808. Review.

23.

New science-based endpoints to accelerate oncology drug development.

Kelloff GJ, Sigman CC.

Eur J Cancer. 2005 Mar;41(4):491-501. Epub 2005 Jan 22. Review.

PMID:
15737552
24.

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW.

Clin Cancer Res. 2004 Jun 1;10(11):3919-26. Review. No abstract available.

25.

Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.

Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC.

Clin Cancer Res. 2004 Jun 1;10(11):3908-18. Review. No abstract available.

26.

Reanalysis of cancer drugs: old drugs, new tricks.

Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ.

Clin Cancer Res. 2004 Jun 1;10(11):3897-907. Review. No abstract available.

27.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. Review. No abstract available.

28.

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Kelloff GJ, Bast RC Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF.

Clin Cancer Res. 2004 Jun 1;10(11):3881-4. Review. No abstract available.

29.

Is inducible nitric oxide synthase a target for chemoprevention?

Crowell JA, Steele VE, Sigman CC, Fay JR.

Mol Cancer Ther. 2003 Aug;2(8):815-23. Review.

30.

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6. No abstract available.

31.

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.

Clin Cancer Res. 2002 Feb;8(2):314-46.

32.

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC.

Urology. 2001 Apr;57(4 Suppl 1):46-51.

PMID:
11295594
33.

Surrogate end-point biomarkers in chemopreventive drug development.

Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ.

IARC Sci Publ. 2001;154:13-26. Review.

PMID:
11220652
34.

Potential use of lipoxygenase inhibitors for cancer chemoprevention.

Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ.

Expert Opin Investig Drugs. 2000 Sep;9(9):2121-38. Review.

PMID:
11060797
35.

Retinoids in chemoprevention and differentiation therapy.

Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM.

Carcinogenesis. 2000 Jul;21(7):1271-9. Review.

PMID:
10874003
36.

Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women.

Lawrence JA, Malpas PB, Sigman CC, Kelloff GJ.

J Cell Biochem Suppl. 2000;34:103-14. Review.

PMID:
10762022
37.

Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC.

J Nutr. 2000 Feb;130(2S Suppl):467S-471S. doi: 10.1093/jn/130.2.467S. Review.

PMID:
10721931
38.

Cancer chemoprevention: progress and promise.

Kelloff GJ, Sigman CC, Greenwald P.

Eur J Cancer. 1999 Dec;35(14):2031-8. Review.

PMID:
10711244
39.

Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.

Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA.

Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37. Review.

40.

Cancer chemoprevention: progress and promise.

Kelloff GJ, Sigman CC, Greenwald P.

Eur J Cancer. 1999 Dec;35(13):1755-62. Review.

PMID:
10673988
41.

Progress in cancer chemoprevention.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC.

Ann N Y Acad Sci. 1999;889:1-13. Review.

PMID:
10668477
42.

Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays.

Steele VE, Kelloff GJ, Balentine D, Boone CW, Mehta R, Bagheri D, Sigman CC, Zhu S, Sharma S.

Carcinogenesis. 2000 Jan;21(1):63-7.

PMID:
10607735
43.

Lipoxygenase inhibitors as potential cancer chemopreventives.

Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ.

Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):467-83. Review.

44.

Chemoprevention of prostate cancer: concepts and strategies.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC.

Eur Urol. 1999;35(5-6):342-50. Review.

PMID:
10325487
45.

Preclinical efficacy studies of green and black tea extracts.

Steele VE, Bagheri D, Balentine DA, Boone CW, Mehta R, Morse MA, Sharma S, Sigman CC, Stoner GD, Wargovich MJ, Weisburger JH, Zhu S, Kelloff GJ.

Proc Soc Exp Biol Med. 1999 Apr;220(4):210-2. Review. No abstract available.

PMID:
10202390
46.

Preclinical drug development paradigms for chemopreventives.

Steele VE, Boone CW, Lubet RA, Crowell JA, Holmes CA, Sigman CC, Kelloff GJ.

Hematol Oncol Clin North Am. 1998 Oct;12(5):943-61, v-vi. Review.

PMID:
9888015
47.

Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring.

Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ.

Clin Chem. 1998 Feb;44(2):420-7.

48.

A quantitative structure-toxicity relationships model for the dermal sensitization guinea pig maximization assay.

Enslein K, Gombar VK, Blake BW, Maibach HI, Hostynek JJ, Sigman CC, Bagheri D.

Food Chem Toxicol. 1997 Oct-Nov;35(10-11):1091-8.

PMID:
9463544
49.

Aromatase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):65-78. Review.

50.

Progress in clinical chemoprevention.

Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC.

Semin Oncol. 1997 Apr;24(2):241-52. Review.

PMID:
9129692

Supplemental Content

Loading ...
Support Center